| 摘要 |
This invention comprises methods and pharmaceutical compositions for minimizing in a mammal the uterotrophic effect of a therapeutic compound selected from the group of tamoxifen, droloxifene, raloxifene, idoxifene, centrochroman, levor, meloxifene, TAT-59, GW 5838 or LY-353381, comprising administration of a compound of formulae (I) or (II), wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, or halogens; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH; Y is the moiety (formulae a), R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof. |
